Skip to content
Twitter page opens in new windowLinkedin page opens in new windowInstagram page opens in new window
investorenquiries@pharmaust.com+61 8 9202 6814
PharmAust (PAA)
Cancer Therapeutics Research
PharmAust (PAA)
  • HOME
  • ABOUT
    • Company Overview
    • Board
    • Corporate Directory
  • PIPELINE & TRIALS
    • Therapeutic Pipeline
    • MPL Veterinary Trial Details
    • MPL and Veterinary Trials
    • Veterinary Trial Testimonials
    • MPL and Human Trials
    • Publications
    • Pet Cancer Information Service
    • Motor Neuron Disease Trial
  • INVESTOR CENTRE
    • PhamAust AGM 2022
    • News & Announcements
    • Company Research
    • Financial Reports
    • Annual Reports
    • Investor Presentations
    • Corporate Governance
    • Top 20 Shareholders
  • MEDIA
    • Podcast Episode 18: Dr Kim Agnew, PharmAust
    • Fireside Chat with Dr Roger Aston
    • Fireside Chat with Dr Kim
    • PharmAust Webinar
    • Epichem Webinar
    • BB PAA Video – September 2021
    • OHD Benchtop Flow Reactor Launch
    • Dr Richard Mollard – Full Interview Ticker TV – 17th June 2020
    • Interview with TechInvest – May 2020
    • Dr. Richard Mollard – 6IX Interview March 2020
    • PharmAust In the News
    • PharmAust Videos
    • PharmAust New Cancer Treatment
    • PharmAust and Catalent Commence GMP Tablet Manufacture (Audio)
    • PharmAust on Youtube
  • CONTACT
  • HOME
  • ABOUT
    • Company Overview
    • Board
    • Corporate Directory
  • PIPELINE & TRIALS
    • Therapeutic Pipeline
    • MPL Veterinary Trial Details
    • MPL and Veterinary Trials
    • Veterinary Trial Testimonials
    • MPL and Human Trials
    • Publications
    • Pet Cancer Information Service
    • Motor Neuron Disease Trial
  • INVESTOR CENTRE
    • PhamAust AGM 2022
    • News & Announcements
    • Company Research
    • Financial Reports
    • Annual Reports
    • Investor Presentations
    • Corporate Governance
    • Top 20 Shareholders
  • MEDIA
    • Podcast Episode 18: Dr Kim Agnew, PharmAust
    • Fireside Chat with Dr Roger Aston
    • Fireside Chat with Dr Kim
    • PharmAust Webinar
    • Epichem Webinar
    • BB PAA Video – September 2021
    • OHD Benchtop Flow Reactor Launch
    • Dr Richard Mollard – Full Interview Ticker TV – 17th June 2020
    • Interview with TechInvest – May 2020
    • Dr. Richard Mollard – 6IX Interview March 2020
    • PharmAust In the News
    • PharmAust Videos
    • PharmAust New Cancer Treatment
    • PharmAust and Catalent Commence GMP Tablet Manufacture (Audio)
    • PharmAust on Youtube
  • CONTACT

Author Archives: PharmAust

Chief Executive Officer Appointment

News and Announcements 2023By PharmAust28/08/2023

Chief Executive Officer Appointment (final)

Additional Phase 1 data suggest MPL may inhibit MND

News and Announcements 2023By PharmAust22/08/2023

Additional Phase 1 data suggest MPL may inhibit motor neurone disease (final)

Cohort 3 Pharmacokinetics in MND Patients Completed

News and Announcements 2023By PharmAust09/08/2023

PharmAust Completes Cohort 3 Pharmacokinetics in MND Patients

Appendix 4C and Quarterly Update

News and Announcements 2023By PharmAust31/07/2023

Appendix 4C and Quarterly Update – June 2023

MND Trial Successfully Completes 3rd Patient Cohort

News and Announcements 2023By PharmAust28/07/2023

MND Trial Successfully Completes 3rd Patient Cohort (final)

Canine Trial Update

News and Announcements 2023By PharmAust13/07/2023

PAA Canine Study Update – July 2023_KA & SW

Results show MPL suppresses biomarkers associated with MND

News and Announcements 2023By PharmAust11/07/2023

Results show MPL suppresses biomarkers associated with MND (final)

Louie the Beagle surpasses one year on MPL

News and Announcements 2023By PharmAust06/07/2023

Louie the beagle surpasses one year on MPL (final)

MND Biomarkers and Pharmacodynamics Results

News and Announcements 2023By PharmAust04/07/2023

230704_MND Biomarkers and Pharmacodynamics Results (final)

Results of General Meeting

News and Announcements 2023By PharmAust30/06/2023

230630 Results of General Meeting

→12345…
67891011121314151617181920212223242526272829303132333435363738394041424344454647484950
51→
MENU
  • Home
  • About Us
  • Pipeline & Trials
  • Investor Centre
  • Media
  • Contact Us
SUBSCRIBE TO OUR NEWSLETTER


Facebook
Facebook
fb-share-icon
Twitter
YouTube

PharmAust Follow

PharmAust is a clinical-stage biotech company developing drug discovery IP to treat cancer, viral and neurological diseases. ASX: $PAA FSE: $ECQ

PharmAust
pharmaust PharmAust @pharmaust ·
4 Sep

Great spread on Louie the Beagle in @AustVetMag Australian Veterinarian Magazine - Spring Issue

https://simplebooklet.com/theaustralianveterinarianmagazine_spring_2023_issue21

Reply on Twitter 1698509346102010223 Retweet on Twitter 1698509346102010223 2 Like on Twitter 1698509346102010223 9 Twitter 1698509346102010223
pharmaust PharmAust @pharmaust ·
2 Sep

PharmAust CEO Dr Michael Thurn spoke with @Biotech_Buzz from @StocksDownUnder and @PSR_Insights about the clinical success with our flagship drug, Monepantel (MPL)

🎥 https://youtu.be/oCfvzseRDxQ?si=iBZu_GMBIg5oSiMX

Reply on Twitter 1697769500807176530 Retweet on Twitter 1697769500807176530 2 Like on Twitter 1697769500807176530 13 Twitter 1697769500807176530
pharmaust PharmAust @pharmaust ·
29 Aug

New CEO to take the helm as PharmAust progresses clinical studies

Reply on Twitter 1696342181496443106 Retweet on Twitter 1696342181496443106 2 Like on Twitter 1696342181496443106 7 Twitter 1696342181496443106
Load More

Copyright © 2023 PharmAust. All rights reserved.
nil

Website Design & Digital Marketing Perth by Total Click Solutions

Go to Top